Advertisement



Drug Shortages

Last updated

Medicines on the FDA drug shortage list, with which forms and strengths are affected, who makes them and when supply is expected back.

161 medicines

  • Ciprofloxacin Hydrochloride and Hydrocortisone Being discontinued 1 product · updated October 30, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Cipro, Otic Suspension/Drops, 0.2% base, 1% (NDC 66758-087-70)
    Sandoz Inc.    		 Discontinuation of the manufacturing of NDC 66758-087-70. Authorized generic is available under new NDC 0781-6218-70
    Being discontinued · October 30, 2026

    Uses, warnings and side effects from the FDA label →

  • Metformin Hydrochloride Being discontinued 2 products · updated October 22, 2026

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Metformin Hydrochloride, Tablet, Extended Release, 500 mg (NDC 0378-6002-91)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 A business decision was made was discontinue manufacture of the drug product.
    Being discontinued · October 22, 2026
    Metformin Hydrochloride, Tablet, Extended Release, 1000 mg (NDC 0378-6001-91)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 A business decision was made was discontinue manufacture of the drug product.
    Being discontinued · October 22, 2026

    Uses, warnings and side effects from the FDA label →

  • Enoxaparin Sodium Being discontinued 24 products · updated October 20, 2026

    Hematology

    Product Availability Expected supply / notes
    Lovenox, Injection, 60 mg/.6 mL (NDC 0075-0621-60)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 300 mg/3 mL (NDC 0075-8030-01)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 150 mg/1 mL (NDC 0075-2915-01)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 40 mg/.4 mL (NDC 0075-8014-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 80 mg/.8 mL (NDC 0075-0622-80)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Enoxaparin Sodium, Injection, 30 mg/.3 mL (NDC 0955-1003-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 30 mg/.3 mL (NDC 0075-0624-30)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Enoxaparin Sodium, Injection, 60 mg/.6 mL (NDC 0955-1006-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 80 mg/.8 mL (NDC 0075-8018-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 30 mg/.3 mL (NDC 0075-8013-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Enoxaparin Sodium, Injection, 120 mg/.8 mL (NDC 0955-1012-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 60 mg/.6 mL (NDC 0075-8016-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Enoxaparin Sodium, Injection, 100 mg/1 mL (NDC 0955-1010-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 120 mg/.8 mL (NDC 0075-8022-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 100 mg/1 mL (NDC 0075-8020-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 300 mg/3 mL (NDC 0075-0626-03)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Enoxaparin Sodium, Injection, 150 mg/1 mL (NDC 0955-1015-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 150 mg/1 mL (NDC 0075-8025-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 100 mg/1 mL (NDC 0075-0623-00)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Enoxaparin Sodium, Injection, 40 mg/.4 mL (NDC 0955-1004-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 40 mg/.4 mL (NDC 0075-0620-40)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Enoxaparin Sodium, Injection, 300 mg/3 mL (NDC 0955-1016-01)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Enoxaparin Sodium, Injection, 80 mg/.8 mL (NDC 0955-1008-10)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026
    Lovenox, Injection, 120 mg/.8 mL (NDC 0075-2912-01)
    Sanofi-Aventis U.S. LLC    		 Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation with last lot expected to expire in March 2029.
    Being discontinued · October 20, 2026

    Uses, warnings and side effects from the FDA label →

  • Leuprolide Acetate Being discontinued 1 product · updated October 20, 2026

    Oncology

    Product Availability Expected supply / notes
    Leuprolide Acetate, Injection, 14 mg/2.8 mL (1 mg/0.2 mL) (NDC 70121-2537-6)
    Amneal Pharmaceuticals    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · October 20, 2026

    Uses, warnings and side effects from the FDA label →

  • Molnupiravir Being discontinued 3 products · updated October 20, 2026

    Anti-Infective, Antiviral

    Product Availability Expected supply / notes
    Lagevrio, Capsule, 200 mg (NDC 0006-5055-06)
    Merck Sharp & Dohme LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · October 20, 2026
    Lagevrio, Capsule, 200 mg (NDC 0006-5055-07)
    Merck Sharp & Dohme LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · October 20, 2026
    Lagevrio, Capsule, 200 mg (NDC 0006-5055-09)
    Merck Sharp & Dohme LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · October 20, 2026
  • Lamivudine Being discontinued 2 products · updated October 19, 2026

    Antiviral

    Product Availability Expected supply / notes
    Epivir, Tablet, 150 mg (NDC 49702-203-18)
    ViiV Healthcare Company    		 The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug
    Being discontinued · October 19, 2026
    Epivir, Tablet, 300 mg (NDC 49702-204-13)
    ViiV Healthcare Company    		 The anticipated date that ViiV will cease distribution of the products is approximately April 15, 2027; Discontinuation of the manufacture of the drug
    Being discontinued · October 19, 2026

    Uses, warnings and side effects from the FDA label →

  • Vigabatrin Being discontinued 1 product · updated October 16, 2026

    Neurology

    Product Availability Expected supply / notes
    Vigabatrin, Tablet, 500 mg (NDC 0054-0652-25)
    Hikma Pharmaceuticals USA, Inc.    		 The decision to discontinue this drug product was due to a business decision and not due to any reasons of safety or effectiveness.
    Being discontinued · October 16, 2026

    Uses, warnings and side effects from the FDA label →

  • Dexmedetomidine Being discontinued 2 products · updated October 14, 2026

    Anesthesia

    Product Availability Expected supply / notes
    Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)
    Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)    		 Discontinuation of the manufacture of the drug; Distributed by Avenacy; Contact information: 877-283-6229
    Being discontinued · October 14, 2026
    Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)
    Accord Healthcare Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · April 21, 2026

    Uses, warnings and side effects from the FDA label →

  • Everolimus Being discontinued 15 products · updated October 14, 2026

    Transplant

    Product Availability Expected supply / notes
    Everolimus, Tablet, 1 mg (NDC 49884-283-02)
    Par Health, USA LLC    		 A business decision was made to withdraw from sale.
    Being discontinued · October 14, 2026
    Everolimus, Tablet, .5 mg (NDC 49884-159-02)
    Par Health, USA LLC    		 A business decision was made to withdraw from sale.
    Being discontinued · October 14, 2026
    Everolimus, Tablet, .25 mg (NDC 49884-158-02)
    Par Health, USA LLC    		 A business decision was made to withdraw from sale.
    Being discontinued · October 14, 2026
    Everolimus, Tablet, .75 mg (NDC 49884-160-02)
    Par Health, USA LLC    		 A business decision was made to withdraw from sale.
    Being discontinued · October 14, 2026
    Everolimus, Tablet, 10 mg (NDC 0093-7769-24)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · March 2, 2026
    Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · March 2, 2026
    Everolimus, Tablet, 5 mg (NDC 0093-7767-24)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · March 2, 2026
    Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · March 2, 2026
    Everolimus, Tablet, 2.5 mg (NDC 49884-119-91)
    Endo Pharmaceuticals, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · January 6, 2026
    Everolimus, Tablet, 5 mg (NDC 49884-125-91)
    Endo Pharmaceuticals, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · January 6, 2026
    Everolimus, Tablet, 10 mg (NDC 49884-128-91)
    Endo Pharmaceuticals, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · January 6, 2026
    Everolimus, Tablet, 7.5 mg (NDC 49884-127-91)
    Endo Pharmaceuticals, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · January 6, 2026
    Everolimus, Tablet, 2 mg (NDC 0378-0005-85)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 3, 2025
    Everolimus, Tablet, 5 mg (NDC 0378-0007-85)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 3, 2025
    Everolimus, Tablet, 3 mg (NDC 0378-0006-85)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 3, 2025

    Uses, warnings and side effects from the FDA label →

  • Felodipine Being discontinued 6 products · updated October 7, 2026

    Cardiovascular

    Product Availability Expected supply / notes
    Felodipine, Tablet, Extended Release, 2.5 mg (NDC 0603-3581-21)
    Par Health, USA LLC    		 Discontinuation in the manufacturing of the drug product
    Being discontinued · October 7, 2026
    Felodipine, Tablet, Extended Release, 2.5 mg (NDC 0603-3581-28)
    Par Health, USA LLC    		 Discontinuation in the manufacturing of the drug product
    Being discontinued · October 7, 2026
    Felodipine, Tablet, Extended Release, 5 mg (NDC 0603-3582-21)
    Par Health, USA LLC    		 Discontinuation in the manufacturing of the drug product
    Being discontinued · October 7, 2026
    Felodipine, Tablet, Extended Release, 5 mg (NDC 0603-3582-28)
    Par Health, USA LLC    		 Discontinuation in the manufacturing of the drug product
    Being discontinued · October 7, 2026
    Felodipine, Tablet, Film Coated, Extended Release, 10 mg (NDC 0603-3583-21)
    Par Health, USA LLC    		 Discontinuation in the manufacturing of the drug product
    Being discontinued · October 7, 2026
    Felodipine, Tablet, Film Coated, Extended Release, 10 mg (NDC 0603-3583-28)
    Par Health, USA LLC    		 Discontinuation in the manufacturing of the drug product
    Being discontinued · October 7, 2026

    Uses, warnings and side effects from the FDA label →

  • Fluocinonide Being discontinued 3 products · updated October 2, 2026

    Dermatology

    Product Availability Expected supply / notes
    Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-92)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · October 2, 2026
    Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-30)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · October 2, 2026
    Fluocinonide, Ointment, .5 mg/1 g (NDC 0093-0264-15)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · October 2, 2026

    Uses, warnings and side effects from the FDA label →

  • Ivermectin Being discontinued 1 product · updated September 29, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    STROMECTOL, Tablet, 3 mg (NDC 0006-0032-01)
    Merck Sharp & Dohme LLC    		 Product will be discontinued on 10/31/2026
    Being discontinued · September 29, 2026

    Uses, warnings and side effects from the FDA label →

  • Arsenic Trioxide Being discontinued 2 products · updated September 21, 2026

    Oncology

    Product Availability Expected supply / notes
    Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 63323-637-10)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · September 21, 2026
    Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10)
    Ingenus Pharmaceuticals LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · February 24, 2026

    Uses, warnings and side effects from the FDA label →

  • Rivaroxaban Being discontinued 1 product · updated September 18, 2026

    Hematology

    Product Availability Expected supply / notes
    Xarelto, For Suspension, 155 mg (NDC 50458-575-01)
    Janssen Pharmaceuticals    		 Business Decision
    Being discontinued · September 18, 2026

    Uses, warnings and side effects from the FDA label →

  • Rivastigmine Being discontinued 1 product · updated September 18, 2026

    Neurology

    Product Availability Expected supply / notes
    Rivastigmine, Film, Extended Release, 4.6 mg/24 h (NDC 0378-9070-93)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug.
    Being discontinued · September 18, 2026

    Uses, warnings and side effects from the FDA label →

  • Melphalan Hydrochloride Being discontinued 1 product · updated September 16, 2026

    Oncology

    Product Availability Expected supply / notes
    Melphalan Hydrochloride, Injection, Kit (NDC 63323-760-20)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · September 16, 2026

    Uses, warnings and side effects from the FDA label →

  • Mesalamine Being discontinued 3 products · updated September 16, 2026

    Gastroenterology

    Product Availability Expected supply / notes
    Pentasa, Capsule, Extended Release, 250 mg (NDC 54092-189-81)
    Takeda Pharmaceuticals USA Inc.    		 Product is anticipated to be available until December 31, 2027
    Being discontinued · September 16, 2026
    Pentasa, Capsule, Extended Release, 500 mg (NDC 54092-191-12)
    Takeda Pharmaceuticals USA Inc.    		 Product is anticipated to be available until December 31, 2027
    Being discontinued · September 16, 2026
    Mesalamine, Capsule, Extended Release, .375 g (NDC 0378-1375-78)
    Mylan Pharmaceuticals Inc., a Viatris Company    		 Discontinuation of the manufacture of the drug
    Being discontinued · August 25, 2026

    Uses, warnings and side effects from the FDA label →

  • Cisatracurium Besylate Being discontinued 3 products · updated September 11, 2026

    Analgesia/Addiction

    Product Availability Expected supply / notes
    Cisatracurium Besylate, Injection, 10 mg/5ml (2 mg/mL) Single Dose Vial (NDC 0409-1098-02)
    Hospira, Inc., a Pfizer Company    		 Supply expected to exhaust November 2026; Discontinuation of the manufacture of the drug
    Being discontinued · September 11, 2026
    Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01)
    Hospira, Inc., a Pfizer Company    		 Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug
    Being discontinued · May 6, 2026
    Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)
    Hospira, Inc., a Pfizer Company    		 Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug
    Being discontinued · May 6, 2026

    Uses, warnings and side effects from the FDA label →

  • Micafungin Sodium Being discontinued 2 products · updated September 11, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    Micafungin Sodium, Injection, 10 mg/1 mL (NDC 42023-229-10)
    Par Health, USA LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · September 11, 2026
    Micafungin Sodium, Injection, 20 mg/1 mL (NDC 42023-230-10)
    Par Health, USA LLC    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · September 11, 2026

    Uses, warnings and side effects from the FDA label →

  • Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Being discontinued 1 product · updated September 10, 2026

    Renal

    Product Availability Expected supply / notes
    DELFLEX, Solution, 18.4 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 46163-212-95)
    Fresenius Medical Care North America    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · September 10, 2026
  • Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous Being discontinued 1 product · updated September 9, 2026

    Anti-Infective

    Product Availability Expected supply / notes
    RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02)
    Merck Sharp & Dohme LLC    		 To be discontinued on or near late September 2026.
    Being discontinued · September 9, 2026
  • Glycerol Phenylbutyrate Being discontinued 2 products · updated September 1, 2026

    Inborn Errors

    Product Availability Expected supply / notes
    RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-06)
    Amgen Inc.    		 Discontinuation in the manufacturing of the drug product
    Being discontinued · September 1, 2026
    RAVICTI, Oral Liquid, 1.1 g/1 mL (NDC 75987-050-07)
    Amgen Inc.    		 Discontinuation in the manufacturing of the drug product
    Being discontinued · September 1, 2026

    Uses, warnings and side effects from the FDA label →

  • Insulin Glargine Being discontinued 1 product · updated September 1, 2026

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Rezvoglar, Injection, 100 [iU]/1 mL (NDC 0002-8980-05)
    Eli Lilly and Co.    		 A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
    Being discontinued · September 1, 2026

    Uses, warnings and side effects from the FDA label →

  • Insulin Lispro Being discontinued 2 products · updated September 1, 2026

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05)
    Eli Lilly and Co.    		 A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
    Being discontinued · September 1, 2026
    Humalog Mix 75/25, Injection, 100 [iU]/1 mL (NDC 0002-8233-05)
    Eli Lilly and Co.    		 A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have any questions, the Lilly Answers Center (1-800-545-5979) is available Monday through Friday from 9am to 8pm for assistance.
    Being discontinued · September 1, 2026

    Uses, warnings and side effects from the FDA label →

  • Medroxyprogesterone Acetate Being discontinued 2 products · updated August 31, 2026

    Urology

    Product Availability Expected supply / notes
    PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026.
    Being discontinued · August 31, 2026
    PROVERA, Tablet, 10 mg (NDC 0009-0051-01)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026.
    Being discontinued · August 31, 2026

    Uses, warnings and side effects from the FDA label →

  • Metoprolol Succinate Being discontinued 7 products · updated August 31, 2026

    Cardiovascular

    Product Availability Expected supply / notes
    Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-11)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 31, 2026
    Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-11)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 31, 2026
    Metoprolol Succinate, Tablet, Extended Release, 200 mg (NDC 45963-678-11)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 31, 2026
    Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-96)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 31, 2026
    Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-96)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 31, 2026
    Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-96)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 31, 2026
    Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-11)
    Teva Pharmaceuticals USA, Inc.    		 A business decision was made to discontinue manufacture of the drug.
    Being discontinued · August 31, 2026

    Uses, warnings and side effects from the FDA label →

  • Palovarotene Being discontinued 1 product · updated August 31, 2026

    Musculoskeletal

    Product Availability Expected supply / notes
    SOHONOS, Capsule, 2.5 mg (NDC 15054-0025-1)
    Ipsen Biopharmaceuticals, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · August 31, 2026
  • Potassium Chloride Being discontinued 5 products · updated August 31, 2026

    Cardiovascular, Endocrinology/Metabolism, Gastroenterology

    Product Availability Expected supply / notes
    Cardioplegic Solution, Injection, Solution, 17.6 mg/100 mL; 325.3 mg/100 mL; 119.3 mg/100 mL; 643 mg/100 mL (NDC 65219-258-10)
    Fresenius Kabi USA, LLC    		 Discontinuation of the manufacture of the drug
    Being discontinued · August 31, 2026
    Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-10)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 21, 2025
    Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-05)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 21, 2025
    Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-01)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 21, 2025
    Potassium Chloride, Tablet, Extended Release, 10 meq (NDC 62037-710-01)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · November 21, 2025

    Uses, warnings and side effects from the FDA label →

  • Liraglutide Being discontinued 2 products · updated August 25, 2026

    Endocrinology/Metabolism

    Product Availability Expected supply / notes
    Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)
    Novo Nordisk, Inc.    		 Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
    Being discontinued · August 25, 2026
    Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)
    Teva Pharmaceuticals USA, Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · May 14, 2026

    Uses, warnings and side effects from the FDA label →

  • Disopyramide Phosphate Being discontinued 2 products · updated August 24, 2026

    Cardiovascular

    Product Availability Expected supply / notes
    Norpace CR, Capsule, Extended Release, 100 mg (NDC 0025-2732-31)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · August 24, 2026
    Norpace CR, Capsule, Extended Release, 150 mg (NDC 0025-2742-31)
    Pfizer Inc.    		 Discontinuation of the manufacture of the drug
    Being discontinued · August 24, 2026

    Uses, warnings and side effects from the FDA label →

Reading the list: a medicine stays on the FDA list while any of its products is short. "Available" next to a product means that particular strength or pack can currently be ordered. If your pharmacy cannot fill a prescription, ask the pharmacist or prescriber about another strength, form or an alternative — do not ration or stop a medicine on your own.

Source: FDA Drug Shortages Database, via openFDA. Updated here twice a day; last update October 31, 2026 14:40. openFDA data are not validated for clinical use — confirm with the FDA source or your pharmacist.

Advertisement